These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36888587)

  • 21. Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer.
    Moussa M; Papatsoris A; Dellis A; Chakra MA; Fragkoulis C
    Expert Opin Pharmacother; 2021 Dec; 22(17):2373-2381. PubMed ID: 34187259
    [No Abstract]   [Full Text] [Related]  

  • 22. Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality.
    Bitterman DS; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
    Cancer; 2021 Aug; 127(15):2623-2630. PubMed ID: 33823065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer.
    Tremblay S; Summers-Trasiewicz L; Pouliot F; Crook JM; Ding K; Klotz L; Toren P
    J Urol; 2021 Nov; 206(5):1166-1176. PubMed ID: 34184929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Apalutamide, Erleada®].
    Sautois B; Denis C
    Rev Med Liege; 2022 Oct; 77(10):609-615. PubMed ID: 36226398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three-month Prostate-specific Antigen Level After Androgen Deprivation Therapy Predicts Survival in Patients With Metastatic Castration-sensitive Prostate Cancer.
    Fujimoto N; Shiota M; Matsukawa T; Minato A; Tomisaki I; Ohnishi R; Eto M
    In Vivo; 2021; 35(2):1101-1108. PubMed ID: 33622907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.
    Strum SB; Scholz MC; McDermed JE
    Oncologist; 2000; 5(1):45-52. PubMed ID: 10706649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of Patients with Localized Prostate Cancer in whom Long-Term Successful Androgen Deprivation Therapy was Ceased].
    Araki H; Ito K; Igarashi A; Miura T; Miyazaki Y; Mishina M; Okuno H
    Hinyokika Kiyo; 2022 Nov; 68(11):337-343. PubMed ID: 36458396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT.
    Ayoub Z; Khader J; Bulbul M; Khauli RB; Andraos TY; Shamseddine A; Mukherji D; Geara FB
    BMC Urol; 2022 Dec; 22(1):204. PubMed ID: 36503556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.
    Ji G; Song G; Huang C; He S; Zhou L
    Medicine (Baltimore); 2017 Sep; 96(36):e7823. PubMed ID: 28885333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
    Saad F; Small EJ; Feng FY; Graff JN; Olmos D; Hadaschik BA; Oudard S; Londhe A; Bhaumik A; Lopez-Gitlitz A; Thomas S; Mundle SD; Chowdhury S; Smith MR
    Eur Urol; 2022 Feb; 81(2):184-192. PubMed ID: 34916086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer.
    Schmidt-Hegemann NS; Zamboglou C; Mason M; Mottet N; Hinnen K; De Meerleer G; Cozzarini C; Maingon P; Henry A; Spahn M; Cornford P; Belka C; Wiegel T
    Radiother Oncol; 2023 Jun; 183():109544. PubMed ID: 36813168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extraction of Treatment Information From Electronic Health Records and Evaluation of Testosterone Recovery in Patients With Prostate Cancer.
    Guin S; Jun T; Patel VG; Ayers KL; Deitz M; Cai Y; Zhou X; Tsao CK; Oh WK; Chen R; Liaw BC
    JCO Clin Cancer Inform; 2022 Jun; 6():e2200010. PubMed ID: 35696627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis.
    Guo Z; Lu X; Yang F; Qin L; Yang N; Wu J; Wang H
    Eur J Med Res; 2022 Aug; 27(1):148. PubMed ID: 35953852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
    Boccon-Gibod L; Albers P; Morote J; van Poppel H; de la Rosette J; Villers A; Malmberg A; Neijber A; Montorsi F
    Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
    Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy.
    Beck J; Rouleau M; Lemire F; Neveu B; Déry M; Thériault B; Dubois G; Guérette D; Pouliot F
    Prostate; 2023 May; 83(7):670-677. PubMed ID: 36851864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy.
    Abrahamsson PA; Boccon-Gibod L; Morote J; de Jong IJ; Malmberg A; Neijber A; Albers P
    Eur Urol Focus; 2017 Oct; 3(4-5):470-479. PubMed ID: 28753747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy.
    Stensland KD; Devasia T; Caram MEV; Chapman C; Zaslavsky A; Morgan TM; Hollenbeck BK; Sparks JB; Burns J; Vedapudi V; Duchesne GM; Tsodikov A; Skolarus TA
    JNCI Cancer Spectr; 2022 May; 6(3):. PubMed ID: 35616109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.